胸腺素α1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-14 and is reviewed periodically as new material appears.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
市售的胸腺素α1通常以冻干粉形式提供，溶解后用于注射。其氨基酸组成包括多个酸性残基，因此在中性pH下带负电荷。该肽可溶于水和生理盐水，但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度，溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。
=== Early detection === From May to August 1939 the LZ130 Graf Zeppelin II made flights along Britain's North Sea coast to investigate the 100-metre-high radio towers that were being erected from Portsmouth to Scapa Flow. LZ130 performed a series of radiometric tests and took photographs. German sources report the 12 m Chain Home signals were detected and suspected to be radar; however, the chief investigator was not able to prove his suspicions. Other sources are said to report different results. During the Battle of France, the Germans observed 12 m pulse signals on the western front without being able to recognize their origin and purpose. In mid-June 1940, the Deutsche Versuchsanstalt für Luftfahrt (DVL, German Aeronautic Research Institute) set up a special group under the direction of Professor von Handel and found out that the signals originated from the installations on the coast of the English Channel. Their suspicions were finally proven in the aftermath of the Battle of Dunkirk, when the British were forced to abandon a mobile gun-laying radar (GL Mk. I) station in Normandy. Wolfgang Martini's team of specialists was able to determine the operation of the system. GL was a rather crude system of limited effectiveness, and this led the Germans to have a dim view of British radar systems. However, an effective system requires more than just the radar; plotting and reporting are equally important, and this part of the system was fully developed in Chain Home.
With its central position in Europe, Germany is a transport hub for the continent. Its road network is among the densest in Europe. The motorway (Autobahn) is widely known for having no general federally mandated speed limit for some classes of vehicles. The Intercity Express or ICE train network serves major German cities as well as destinations in neighbouring countries with speeds up to 300 km/h (190 mph). The largest German airports are Frankfurt Airport, Munich Airport and Berlin Brandenburg Airport. The Port of Hamburg is the third-busiest port in Europe and one of the twenty largest container ports in the world. In 2019, Germany was the world's seventh-largest consumer of energy. All German nuclear power plants were phased out in 2023. Germany meets its power demands using 40% renewable sources (2018), and has been called an "early leader" in solar panels and offshore wind. The German energy transition (Energiewende) is the recognised move to a sustainable economy by means of energy efficiency and renewable energy, with the country being called "the world's first major renewable energy economy". Germany has reduced its primary energy consumption by 11% between 1990 and 2015 and set itself goals of reducing it by 30% until 2030 and 50% by 2050. The country is committed to the Paris Agreement and several other treaties promoting biodiversity, low emission standards, and water management. As of 2017, Germany's household recycling rate is among the highest in the world, at around 65%. In 2023, Germany was the 14th highest emitting nation of greenhouse gases.
Reduced dissection (cutting) of the nasal tissues—no columellar incision Decreased potential for the excessive reduction (cutting) of the nasal-tip support Reduced post-operative edema Decreased visible scarring Decreased iatrogenic (inadvertent) damage to the nose, by the surgeon Increased availability for effecting in situ procedural and technical changes Palpation that allows the surgeon to feel the interior changes effected to the nose Shorter operating room time Quicker post-surgical recovery and convalescence for the patient On the other hand, benefits of an open procedure include better visualization for surgical access, granting the surgeon greater tip precision. The open approach is therefore usually preferred for revision rhinoplasty. While the open technique provides direct visualization and greater control in complex cases, systematic reviews and meta-analyses show no significant difference in long-term functional or aesthetic outcomes (eg, NOSE and ROE scores) when compared to the closed approach. The choice of approach is primarily driven by surgeon expertise and the specific anatomical requirements of the patient.
Sources: en.wikipedia.org
To date, at least, there is little sign of a serious effort to forge a meaningful anti-American alliance ... From the traditional perspective of balance-of-power theory, this situation is surely an anomaly. Power in the international system is about as unbalanced as it has ever been, yet balancing tendencies are remarkably mild. It is possible to find them, but one has to squint pretty hard to do it.
The Thiambutenes are a family of opioid analgesic drugs developed at the British research laboratory of Burroughs-Wellcome in the late 1940s. The parent compound thiambutene has no analgesic effects, but several compounds from this group are analgesics with around the same potency as morphine. Notable compounds include dimethylthiambutene, diethylthiambutene, ethylmethylthiambutene, pyrrolidinylthiambutene and piperidylthiambutene. Of these, ethylmethylthiambutene is the most potent, with 1.3x the potency of morphine, pyrrolidinylthiambutene is the least potent at 0.7x, and the rest are all around the same potency as morphine. Diethylthiambutene has been the most widely used, mainly in veterinary medicine. All of these compounds produced anticholinergic and antihistamine side effects, except for two of the weaker compounds diallylthiambutene and morpholinylthiambutene. They also all have a chiral centre on the alpha carbon (where the R1 group is attached) and so have two stereoisomers, with the dextro isomer being the more potent in all cases, although both isomers are active. Three of these compounds are explicitly listed as illegal drugs under UN convention, diethylthiambutene, dimethylthiambutene and ethylmethylthiambutene, and so are illegal throughout the world, but the rest will only be illegal in countries such as the US, Australia and New Zealand that have laws equivalent to the Federal Analog Act.
This amalgam was then heated in an atmosphere of hydrogen gas to remove the mercury, leaving pure radium metal. Later that same year, E. Ebler isolated radium metal by thermal decomposition of its azide, Ra(N3)2. Radium metal was first industrially produced at the beginning of the 20th century by Biraco, a subsidiary company of Union Minière du Haut Katanga (UMHK) in its Olen plant in Belgium. The metal became an important export of Belgium from 1922 up until World War II. The general historical unit for radioactivity, the curie, is based on the radioactivity of 226Ra. It was originally defined as the radioactivity of one gram of radium-226, but the definition was later refined to be 3.7×1010 disintegrations per second.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.